JP2016535772A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016535772A5 JP2016535772A5 JP2016551466A JP2016551466A JP2016535772A5 JP 2016535772 A5 JP2016535772 A5 JP 2016535772A5 JP 2016551466 A JP2016551466 A JP 2016551466A JP 2016551466 A JP2016551466 A JP 2016551466A JP 2016535772 A5 JP2016535772 A5 JP 2016535772A5
- Authority
- JP
- Japan
- Prior art keywords
- optionally substituted
- group
- hydrogen atom
- methyl
- salt
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2013232571 | 2013-11-08 | ||
| JP2013232571 | 2013-11-08 | ||
| JP2014128562 | 2014-06-23 | ||
| JP2014128562 | 2014-06-23 | ||
| PCT/JP2014/080005 WO2015068856A1 (en) | 2013-11-08 | 2014-11-05 | Pyrazole for the treatment autoimmune disorders |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016535772A JP2016535772A (ja) | 2016-11-17 |
| JP2016535772A5 true JP2016535772A5 (OSRAM) | 2017-09-21 |
| JP6412148B2 JP6412148B2 (ja) | 2018-10-24 |
Family
ID=51999482
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016551466A Active JP6412148B2 (ja) | 2013-11-08 | 2014-11-05 | 自己免疫疾患治療のためのピラゾール |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US9321757B2 (OSRAM) |
| EP (1) | EP3066094B1 (OSRAM) |
| JP (1) | JP6412148B2 (OSRAM) |
| CN (1) | CN105899505B (OSRAM) |
| BR (1) | BR112016010041B1 (OSRAM) |
| CA (1) | CA2929316C (OSRAM) |
| EA (1) | EA201690952A1 (OSRAM) |
| ES (1) | ES2777123T3 (OSRAM) |
| TW (1) | TW201605847A (OSRAM) |
| UY (1) | UY35821A (OSRAM) |
| WO (1) | WO2015068856A1 (OSRAM) |
Families Citing this family (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201311891D0 (en) | 2013-07-03 | 2013-08-14 | Glaxosmithkline Ip Dev Ltd | Novel compound |
| GB201311888D0 (en) | 2013-07-03 | 2013-08-14 | Glaxosmithkline Ip Dev Ltd | Novel compounds |
| TW201605847A (zh) * | 2013-11-08 | 2016-02-16 | 武田藥品工業股份有限公司 | 雜環化合物 |
| US20180228907A1 (en) | 2014-04-14 | 2018-08-16 | Arvinas, Inc. | Cereblon ligands and bifunctional compounds comprising the same |
| JP6936236B2 (ja) * | 2016-02-18 | 2021-09-15 | エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | 治療化合物、組成物及びその方法の使用 |
| WO2017170830A1 (ja) * | 2016-03-31 | 2017-10-05 | 武田薬品工業株式会社 | 複素環化合物 |
| CN106317952B (zh) * | 2016-08-19 | 2018-03-09 | 福建中烟工业有限责任公司 | 一种增白组合物、其制备方法及用途 |
| JP2019196309A (ja) * | 2016-09-15 | 2019-11-14 | 武田薬品工業株式会社 | 複素環化合物 |
| US10414753B2 (en) * | 2016-10-26 | 2019-09-17 | Rigel Pharmaceuticals, Inc. | Amide compounds and method for making and using |
| JOP20180011A1 (ar) | 2017-02-16 | 2019-01-30 | Gilead Sciences Inc | مشتقات بيرولو [1، 2-b]بيريدازين |
| WO2018166993A2 (en) | 2017-03-14 | 2018-09-20 | F. Hoffmann-La Roche Ag | Pyrazolochlorophenyl compounds, compositions and methods of use thereof |
| JP7256757B2 (ja) | 2017-05-22 | 2023-04-12 | エフ． ホフマン－ラ ロシュ アーゲー | 処置用化合物及び組成物、並びにその使用方法 |
| EP3684366A4 (en) | 2017-09-22 | 2021-09-08 | Kymera Therapeutics, Inc. | CRBN LIGANDS AND USES OF THE LATEST |
| WO2019060742A1 (en) | 2017-09-22 | 2019-03-28 | Kymera Therapeutics, Inc | AGENTS FOR DEGRADING PROTEINS AND USES THEREOF |
| US11065231B2 (en) | 2017-11-17 | 2021-07-20 | Arvinas Operations, Inc. | Compounds and methods for the targeted degradation of interleukin-1 receptor- associated kinase 4 polypeptides |
| WO2019111218A1 (en) | 2017-12-08 | 2019-06-13 | Cadila Healthcare Limited | Novel heterocyclic compounds as irak4 inhibitors |
| IL315310A (en) | 2017-12-26 | 2024-10-01 | Kymera Therapeutics Inc | Irak degraders and uses thereof |
| EP3737675A4 (en) | 2018-01-12 | 2022-01-05 | Kymera Therapeutics, Inc. | Crbn ligands and uses thereof |
| WO2019140380A1 (en) | 2018-01-12 | 2019-07-18 | Kymera Therapeutics, Inc. | Protein degraders and uses thereof |
| IL277408B2 (en) * | 2018-04-05 | 2024-08-01 | Merck Patent Gmbh | Heteroaryl compounds as type ii irak inhibitors and uses thereof |
| EP3553061A1 (en) * | 2018-04-12 | 2019-10-16 | Centre National De La Recherche Scientifique (Cnrs) | New inhibitors of bone resorption |
| US11292792B2 (en) | 2018-07-06 | 2022-04-05 | Kymera Therapeutics, Inc. | Tricyclic CRBN ligands and uses thereof |
| WO2020010227A1 (en) | 2018-07-06 | 2020-01-09 | Kymera Therapeutics, Inc. | Protein degraders and uses thereof |
| TWI842978B (zh) | 2018-07-13 | 2024-05-21 | 美商基利科學股份有限公司 | 衍生物 |
| KR102545594B1 (ko) | 2018-07-31 | 2023-06-21 | 록쏘 온콜로지, 인코포레이티드 | (s)-5-아미노-3-(4-((5-플루오로-2-메톡시벤즈아미도)메틸)페닐)-1-(1,1,1-트리플루오로프로판-2-일)-1h-피라졸-4-카르복스아미드의 분무-건조된 분산물 및 제제 |
| KR102625224B1 (ko) | 2018-10-31 | 2024-01-15 | 주식회사 큐로젠 | 피라졸-온 유도체를 유효성분으로 포함하는 자가면역질환의 예방, 개선 또는 치료용 조성물 |
| US11352350B2 (en) | 2018-11-30 | 2022-06-07 | Kymera Therapeutics, Inc. | IRAK degraders and uses thereof |
| CN118806758A (zh) | 2019-11-05 | 2024-10-22 | 德米拉公司 | 用于治疗以炎症为特征的皮肤病状的包括irak4抑制剂的局部组合物 |
| EP4076520A4 (en) | 2019-12-17 | 2024-03-27 | Kymera Therapeutics, Inc. | Irak degraders and uses thereof |
| WO2021127283A2 (en) | 2019-12-17 | 2021-06-24 | Kymera Therapeutics, Inc. | Irak degraders and uses thereof |
| TW202210483A (zh) | 2020-06-03 | 2022-03-16 | 美商凱麥拉醫療公司 | Irak降解劑之結晶型 |
| EP4172163A4 (en) * | 2020-06-30 | 2024-07-24 | Dermira, Inc | IRAK4 INHIBITORS AND TOPICAL USES THEREOF |
| TW202241891A (zh) | 2020-12-30 | 2022-11-01 | 美商凱麥拉醫療公司 | Irak降解劑及其用途 |
| JP2024506656A (ja) | 2021-02-15 | 2024-02-14 | カイメラ セラピューティクス， インコーポレイテッド | Ｉｒａｋ４分解剤およびその使用 |
| US12097261B2 (en) | 2021-05-07 | 2024-09-24 | Kymera Therapeutics, Inc. | CDK2 degraders and uses thereof |
| WO2023076556A1 (en) | 2021-10-29 | 2023-05-04 | Kymera Therapeutics, Inc. | Irak4 degraders and synthesis thereof |
| JP2025504059A (ja) | 2022-01-31 | 2025-02-06 | カイメラ セラピューティクス， インコーポレイテッド | Ｉｒａｋデグレーダー及びその使用 |
| JP2025513716A (ja) | 2022-03-23 | 2025-04-30 | ライジェル・ファーマシューティカルズ・インコーポレイテッド | Ｉｒａｋ阻害剤としてのピリミド－２－イル－ピラゾール化合物 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20100160324A1 (en) | 2004-12-30 | 2010-06-24 | Astex Therapeutics Limited | Pyrazole derivatives as that modulate the activity of cdk, gsk and aurora kinases |
| AU2007314342B2 (en) * | 2006-10-31 | 2013-02-21 | Merck Sharp & Dohme Corp. | Anilinopiperazine Derivatives and methods of use thereof |
| EP2070924A1 (de) * | 2007-12-10 | 2009-06-17 | Bayer Schering Pharma Aktiengesellschaft | Neue 2-Hetarylthiazol-4-carbonsäureamid-Derivative, deren Herstellung und Verwendung als Arzneimittel |
| TW201103904A (en) | 2009-06-11 | 2011-02-01 | Hoffmann La Roche | Janus kinase inhibitor compounds and methods |
| UA110324C2 (en) * | 2009-07-02 | 2015-12-25 | Genentech Inc | Jak inhibitory compounds based on pyrazolo pyrimidine |
| JP2012254939A (ja) * | 2009-10-07 | 2012-12-27 | Astellas Pharma Inc | オキサゾール化合物 |
| CA2794801C (en) * | 2010-04-07 | 2019-01-15 | F. Hoffmann-La Roche Ag | Pyrazol-4-yl-heterocyclyl-carboxamide compounds and methods of use |
| TW201605847A (zh) * | 2013-11-08 | 2016-02-16 | 武田藥品工業股份有限公司 | 雜環化合物 |
-
2014
- 2014-11-05 TW TW103138324A patent/TW201605847A/zh unknown
- 2014-11-05 US US14/533,326 patent/US9321757B2/en active Active
- 2014-11-05 JP JP2016551466A patent/JP6412148B2/ja active Active
- 2014-11-05 EP EP14805371.3A patent/EP3066094B1/en active Active
- 2014-11-05 EA EA201690952A patent/EA201690952A1/ru unknown
- 2014-11-05 UY UY0001035821A patent/UY35821A/es not_active Application Discontinuation
- 2014-11-05 ES ES14805371T patent/ES2777123T3/es active Active
- 2014-11-05 BR BR112016010041-7A patent/BR112016010041B1/pt active IP Right Grant
- 2014-11-05 CN CN201480072420.9A patent/CN105899505B/zh active Active
- 2014-11-05 CA CA2929316A patent/CA2929316C/en active Active
- 2014-11-05 WO PCT/JP2014/080005 patent/WO2015068856A1/en not_active Ceased
-
2016
- 2016-04-25 US US15/137,161 patent/US9890145B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016535772A5 (OSRAM) | ||
| JP2018519323A5 (OSRAM) | ||
| JP2016536363A5 (OSRAM) | ||
| JP2017502940A5 (OSRAM) | ||
| JP2016540811A5 (OSRAM) | ||
| CA2796967A1 (en) | Heterocyclic derivatives as alk inhibitors | |
| JP2017513894A5 (OSRAM) | ||
| JP2017514830A5 (OSRAM) | ||
| JP2015501799A5 (OSRAM) | ||
| JP2014511869A5 (OSRAM) | ||
| JP2010506825A5 (OSRAM) | ||
| HRP20170112T1 (hr) | Supstituirani spojevi piridin-2-karboksamida kao kinazni inhibitori signalne regulacije apoptoze | |
| CN105636951A (zh) | 酰胺类衍生物及其可药用盐、其制备方法及其在医药上的应用 | |
| JP2016537389A5 (OSRAM) | ||
| JP2016530322A5 (OSRAM) | ||
| JP2013531074A5 (OSRAM) | ||
| JP2016528273A5 (OSRAM) | ||
| JP2015535851A5 (OSRAM) | ||
| JP2020500916A5 (OSRAM) | ||
| JP2017505293A5 (OSRAM) | ||
| JP2016529235A5 (OSRAM) | ||
| JP2017517538A5 (OSRAM) | ||
| NZ629636A (en) | Liver x receptor (lxr) modulators for the treatment of dermal diseases, disorders and conditions | |
| JP2017520540A5 (OSRAM) | ||
| JP2017519818A5 (OSRAM) |